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Background:  Inflammation, determined by elevation of C-reactive protein (CRP) in response to interleukin 6 (IL-6), is associated with 
cardiovascular disease and the burden of atrial fibrillation (AF). The relationship between CRP and IL-6 and future cardiovascular events in patients 
with AF needs further elucidation.
Methods:  In the RELY study 18113 patients with AF and at least one additional risk factor for stroke were randomized to dabigatran or warfarin 
and followed for 2.0 years median treatment duration. Blood samples were obtained at randomization. We analyzed plasma concentrations of hsCRP 
(n=6206) using immunoturbidimetric assay (Abbott) and hsIL-6 (n=6217) using ELISA technique (R&D Systems) at the UCR-laboratory (Uppsala 
University), and evaluated their associations to stroke or systemic embolism (SE); myocardial infarction (MI); vascular death; major bleed; and 
the composite outcome of ischemic stroke, SE, MI, pulmonary embolism and death, using a Cox proportional hazards model adjusting for baseline 
demographics including CHADS2 risk factors, pre-study anticoagulants, statins, and study drug.
Results:  Biomarkers were divided in quartile groups. A separate analysis of hsCRP with cut off levels in accordance with CDC/AHA guidelines for 
vascular risk (<1; 1 to <3; and ≥3 mg/L) yielded similar results.
Conclusion: In AF patients, IL-6 was predictive of stroke and both inflammatory markers were associated with an increased risk of vascular death 
and cardiovascular events.
IL-6 HR (95% CI)
Outcome
Group1:
IL-6
≤1.5
ng/L
N=1620
No of pts (%/yr)
Group2:
IL-6
1.6-2.4 ng/L
N=1551
No of pts (%/yr)
Group3:
IL-6
2.5-4.0 ng/L
N=1486
No of pts (%/yr)
Group4:
IL-6
≥4.1
ng/L
N=1560
No of pts (%/yr)
Group2 vs Group1 Group3 vs Group1 Group4 vs Group1
p-value
effect of
biomarker level
Stroke/SE 26 (0.75) 44 (1.33) 58 (1.85) 57 (1.80) 1.59 (0.97-2.58) 2.14 (1.34-3.42) 2.01 (1.25-3.23) 0.0091
MI 17 (0.49) 20 (0.60) 30 (0.96) 36 (1.14) 1.10 (0.57-2.10) 1.61 (0.88-2.94) 1.86 (1.03-3.37) 0.1014
Death from vascular cause 31 (0.89) 54 (1.63) 74 (2.36) 141 (4.45) 1.60 (1.03-2.50) 2.17 (1.42-3.32) 3.71 (2.50-5.52) <.0001
Composite outcome 88 (2.53) 133 (4.02) 159 (5.08) 256 (8.08) 1.40 (1.07-1.84) 1.68 (1.29-2.18) 2.53 (1.97-3.24) <.0001
Major bleed 55 (1.58) 71 (2.15) 87 (2.78) 123 (3.88) 1.21 (0.85-1.73) 1.51 (1.08-2.13) 2.05 (1.48-2.84) <.0001
CRP HR (95% CI)
Outcome
Group1:
CRP
≤1.3
mg/L
N=1578
No of pts (%/yr)
Group2:
CRP
1.4-2.7 mg/L
N=1567
No of pts (%/yr)
Group3:
CRP
2.8-5.9 mg/L
N=1524
No of pts (%/yr)
Group4:
CRP
≥6.0 mg/L
N=1537
No of pts (%/yr)
Group2 vs Group1 Group3 vs Group1 Group4 vs Group1
p-value
effect of
biomarker level
Stroke/SE 37 (1.10) 44 (1.32) 52 (1.62) 51 (1.61) 1.19 (0.77-1.85) 1.42 (0.93-2.18) 1.38 (0.90-2.12) 0.3592
MI 14 (0.42) 26 (0.78) 25 (0.78) 38 (1.20) 1.99 (1.04-3.83) 1.94 (1.00-3.75) 2.94 (1.58-5.48) 0.0078
Death from vascular cause 60 (1.79) 52 (1.56) 75 (2.34) 111 (3.50) 0.84 (0.58-1.22) 1.19 (0.84-1.67) 1.62 (1.18-2.23) 0.0004
Composite outcome 123 (3.66) 132 (3.97) 161 (5.03) 218 (6.88) 1.09 (0.85-1.39) 1.32 (1.04-1.67) 1.73 (1.39-2.17) <.0001
Major bleed 71 (2.12) 81 (2.43) 82 (2.56) 101 (3.19) 1.19 (0.87-1.64) 1.22 (0.89-1.68) 1.53 (1.12-2.08) 0.0565
